Nomir Medical’s Noveon(R) Device Achieves 76 Percent Response Rate in Pivotal Trial for the Treatment of Onychomycosis
3/5/2009 10:08:25 AM
WALTHAM, Mass.--(BUSINESS WIRE)--Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today positive preliminary data from the pivotal product registration trial evaluating the Company’s advanced Noveon® direct optical energy device for the treatment of onychomycosis (toenail fungus). The Noveon is a light-based system that photo-biologically targets the elimination of bacterial and fungal infections through a unique, near-infrared, photo-inactivation effect, while preserving healthy tissue and promoting recovery.
comments powered by